Merck & Co.
AWARDS
NEWS
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 20, 2020.
Clovis Oncology’s Rubraca remained the only PARP inhibitor approved for prostate cancer for only a handful of days. Today, that medication is joined by AstraZeneca’s and Merck’s powerhouse PARP inhibitor, Lynparza.
Clinical trial updates not related to COVID-19 are on the upswing, partly because some companies are announcing trial information ahead of the upcoming American Society of Clinical Oncology virtual meeting being held at the end of the month. Here’s a look.
The company announced positive data from the Phase III KEYNOTE-355 trial looking at Keytruda in combination with chemotherapy as first-line treatment for metastatic triple-negative breast cancer.
The Lynparza approval isn’t as broad as the Zejula approval, with Lynparza not approved for use in patients with homologous recombination deficiencies.
Together, the companies will focus on the generation of novel small molecule inhibitors against specified deubiquitinase (DUB) targets, specifically for the treatment of neurodegenerative and other diseases.
JOBS
IN THE PRESS